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Introduction: The development of complex renal cysts after crizo-
tinib treatment for non–small-cell lung cancer (NSCLC) is a reported 
side effect. However, its occurrence and characteristics have not been 
reported.
Methods: Medical records and computed tomography images of 
crizotinib-treated patients in three prospective clinical trials were 
reviewed. The size and Bosniak category of the renal cysts before 
and after crizotinib treatment were determined. Patients’ clinical 
characteristics, tumor stage, treatment response, renal function, and 
outcomes were analyzed.
Results: During December 2010 to March 2013, we enrolled 32 
patients who received crizotinib. There were 23 patients who had renal 
cysts before crizotinib. The median follow-up time was 493 days. 
Seven patients (22%, six with baseline renal cyst and one without 
baseline renal cyst) had significant renal cyst change. Four (13% of all) 
had new complex renal cysts. The median time from crizotinib treat-
ment to first recognization of significant renal cyst change was 77 days. 
After stopping crizotinib, complex renal cysts regressed significantly. 
Patients with significant renal cyst change received more previous anti-
cancer therapy (median, 5 lines versus 3 lines, p = 0.04) and received 
crizotinib for longer duration (median, 956 days versus 248 days, 
p = 0.007) compared with those without significant renal cyst change.
Conclusions: Change of renal cysts after crizotinib treatment is not 
uncommon. Development of complex renal cysts reverses after stop-
ping crizotinib.
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(J Thorac Oncol. 2014;9: 1720–1725)
Crizotinib is an inhibitor of several receptor tyrosine kinases, including anaplastic lymphoma kinase (ALK), 
hepatocyte growth factor receptor (HGFR, c-Met),1 and 
c-ros oncogene 1.2 It has been approved for the treatment of 
advanced ALK-positive non–small-cell lung cancer (NSCLC) 
in many countries. The development of complex renal cyst 
has been observed in seven (4%) patients as stated in the lat-
est label of crizotinib published by the US Food and Drug 
Administration (FDA).3 However, its occurrence and charac-
teristics have not been reported.
Renal cysts are common radiologic findings. Bosniak 
published the well-known classification of renal cysts based 
on computed tomography (CT) scan in 1986.4 The classifica-
tion was proven to be correlated with the risk of malignancy 
by several studies.5,6 In general, more complex renal cysts 
are at increased risk of being malignant.6 We systematically 
reviewed renal cyst development by size and Bosniak cate-
gory in crizotinib-treated patients.
PATIENTS AND METHODS
This study enrolled patients who received crizo-
tinib in three prospective clinical trials [PROFILE 1005 
(NCT00932451),7 PROFILE 1007 (NCT00932893),8 and an 
exploratory study of crizotinib efficacy (NCT01637597)] at 
the National Taiwan University Hospital during December 
2010 to March 2013 for advanced ALK-positive NSCLC. The 
clinical trials were approved by the Research Ethics Committee 
and all patients gave written informed consent. The patients 
were followed up by 5-mm slice chest and abdominal CT scans 
as dictated by the study protocol. Those who did not receive 
CT scan follow-up for any reason were excluded. Those with 
only noncontrast CT follow-up were also excluded. Although 
noncontrast enhanced CT scans may also identify renal cysts, 
CT scans with contrast enhancement, on which the Bosniak 
classification is based,4 are more valuable for the evaluation of 
renal cystic lesions. The patient’s clinical characteristics, use 
of previous anticancer therapy, details of crizotinib treatment, 
and clinical outcomes were recorded.
A radiologist, who was blinded to the patients’ clinical 
characteristics, reviewed the CT scans before and after the start 
of crizotinib. Renal cysts were recorded individually based on 
the maximum diameter of axial section on contrast-enhanced 
CT. The Bosniak category4–6 of renal cystic disease was given. 
Significant renal cyst change was defined as the presence 
of new renal cysts more than 4 mm in size, enlargement or 
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regression of previous renal cysts of more than 4 mm, or com-
plicated renal cysts (Bosniak category IIF or higher) that were 
initially simple cysts (Bosniak category I).
Continuous variables were reported as median with 
upper to third quartiles. The Mann-Whitney U test was used 
as appropriate. Categorical data were compared using Fisher’s 
exact test. Statistical significance was set at p < 0.05.
RESULTS
Patient Demographic and 
Clinical Characteristics
During December 2010 to March 2013, there were 39 
patients who were enrolled in crizotinib trials. Seven patients 
(four with no follow-up CT and three with noncontrast CT fol-
low-up) were excluded. The remaining 32 were enrolled into 
this study. Among the patients, 15 (47%) were male, 21 (66%) 
were never smokers, and 31 (97%) had adenocarcinoma. The 
median age was 58 years (range, 32–82).
Development of Renal Cysts after Crizotinib
There were 23 patients (72%) who had renal cysts 
before receiving crizotinib treatment. All cysts were Bosniak 
category I. During the treatment period, seven patients (22%, 
six with baseline renal cyst and one without baseline renal 
cyst) had significant renal cyst change (Table 1). Four (13% of 
all) had new complex renal cysts. The median time from crizo-
tinib to first recognization of significant renal cyst change was 
77 (range, 42–203) days.
Patient 1 was the representative case of complex renal 
cyst formation. She had simple renal cysts upon enrollment 
into the trial (Fig. 1A). Significant renal cyst change had been 
noted since treatment day 42. CT showed that her previous renal 
cysts had enlarged and multiple new renal cysts developed 
bilaterally 3 months after crizotinib treatment (Figs. 1B, 2A). 
The renal cysts had thickened and enhanced septa, corre-
sponding to category III renal cysts (Fig. 2A). Six months 
(Figs. 1C, 2B) following crizotinib, the renal cysts become 
more complex. In Figure 2B, the right renal cyst had irregular 
margins and extended to abut the ascending colon. The left 
renal cyst also had irregular margins and extended to abut 
the left psoas muscle. Both were large, bizarre cysts, indi-
cating category IV renal cysts. Category III or higher renal 
cysts on the Bosniak classification are associated with high 
risk of malignancy4–6 and surgical excision should be consid-
ered. However, because the patient had advanced lung cancer 
and the complex renal cysts occurred bilaterally, such major 
operation may be at risks. Therefore, immediate excision was 
not performed after detection of the cysts. Her creatinine 
level increased from 0.9 mg/dL (pretreatment) to 2.02 mg/dL 
6 months after treatment. She did not have significant diarrhea 
or dehydration. The urine analysis was within normal limit. 
Crizotinib was held for 6 weeks for decreased renal func-
tion. Her creatinine level decreased to 1.1 mg/dL. Follow-up 
CT scan found significantly decreased size of the renal cysts 
(Fig. 2D). Thus, crizotinib was resumed and biopsy or exci-
sion was not performed. Seventeen months after crizotinib 
treatment, her renal cysts became very large and complex 
(Figs. 1E, 2C), indicating category IV renal cysts. However, 
her renal function was not affected. Enlargement of the lung 
tumor and disease progression were noted. Crizotinib was 
stopped and local radiotherapy was started for lung tumor 
control. Two month after stopping crizotinib, her renal cysts 
regressed again (Fig. 1F).
Patient 2 was another representative case of complex 
renal cyst formation. He only had simple renal cysts upon 
enrollment into the trial (Fig. 3A). Significant renal cyst change 
had been noted since treatment day 84. CT scan 12 months 
(Fig. 3B) and 27 months (Fig. 3C) after crizotinib treatment 
showed progressively increasing numbers of complex cysts 
FIGURE 1.  Renal cyst evolution in 
patient 1. A, Abdominal contrast-
enhanced CT scan with reconstruc-
tion to coronal view before crizotinib 
treatment. B, Three months after 
crizotinib, there were new renal 
cysts bilaterally. C, Six months after 
crizotinib treatment, there were mul-
tiple bilateral bizarre complex renal 
cysts. Crizotinib was stopped. D, Six 
weeks after withholding crizotinib, 
bilateral renal cysts decreased in size. 
Crizotinib was resumed. E, Seventeen 
months after crizotinib treatment, 
the renal cysts became very large and 
complex. Crizotinib was stopped and 
radiotherapy was started because 
of lung cancer progression. F, Two 
months after stopping crizotinib, the 
renal cysts regressed.
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bilaterally (Bosniak category III). His renal function was sta-
ble and urine analysis was unremarkable.
Because of lung cancer progression, crizotinib was 
held and local radiotherapy given. Two months after stopping 
crizotinib, the renal cysts regressed significantly (Fig. 3D). 
Crizotinib was resumed after completing radiotherapy. Two 
months after resuming crizotinib, the renal cysts progressed 
again (Fig. 3E). Because of progressive bony metastases, 
crizotinib was stopped after 32 months of treatment. He was 
then given alectinib for crizotinib-resistant ALK-positive lung 
cancer. Four months later, the renal cysts regressed, and only 
small residual cysts were left (Fig. 3F).
Details of other patients are shown in Table 1.
Comparison of Clinical Features between 
Patients with and those Without 
Significant Renal Cyst Change
Comparisons of clinical characteristics between those 
with and those without significant renal cyst change are 
shown in Table 2. Patients with significant renal cyst change 
have more previous anti-tumor therapy (p = 0.04) and longer 
duration on crizotinib (p = 0.007). The progression free sur-
vival was not significantly different between the two groups 
(median, 509 days versus 210 days, p = 0.09) because of the 
small number of patients. The demographic characteristics 
and crizotinib treatment duration were not significantly dif-
ferent between patients with and without baseline renal cyst 
(Table 3). Further analysis of patients with renal cyst change 
FIGURE 2.  Parts of CT scans of patient 1 after crizotinib treatment. A, Three months after crizotinib. There were thickened 
and enhanced septa in the left renal cyst (arrow), indicating a category III renal cyst. B, Six months after crizotinib. The right 
renal cyst had irregular margins and extended to abut the ascending colon. The left renal cyst also had irregular margins and 
extended to abut the left psoas muscle (arrows). Both were category IV renal cysts. C, Seventeen months after crizotinib. The 
left renal cyst had irregular margins and enhancing solid part (arrows), indicating a category IV renal cyst.
FIGURE 3.  Evolution of renal cysts 
in patient 2. A, Before crizotinib, 
abdominal contrast-enhanced CT 
at the level of renal veins revealed 
a simple cyst in the left kidney. B, 
One year after crizotinib treatment, 
the left renal cyst had enlarged and 
became complex. C, Twenty-seven 
Months after crizotinib treatment, 
the left cyst became larger and there 
was a new complex cyst on the 
right. Crizotinib was stopped. D, Two 
months after withholding crizotinib, 
renal cysts in both kidneys regressed. 
E, CT scan 2 months after resuming 
crizotinib showed that the renal cysts 
had progressed. F, Four months after 
shifting crizotinib to alectinib, the 
renal cysts regressed, and only small 
residual cysts were left.
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(n = 7), patients with baseline renal cyst but without renal cyst 
change (n = 17) and patients without baseline renal cyst and 
without renal cyst change (n = 8) revealed that crizotinib treat-
ment duration for the three groups were 956 (583–963) days, 
238 (136–455) days, and 311 (78–643) days, respectively. 
Patients with renal cyst change had longer crizotinib treatment 
duration than patients without renal cyst change, whether they 
had baseline renal cyst (p = 0.008) or not (p = 0.04). Among 
patients without renal cyst change, crizotinib treatment dura-
tion did not differ significantly between patients with or with-
out baseline renal cyst (p = 0.68).
DISCUSSION
We described changes in renal cysts in patients who 
received crizotinib for ALK-positive advanced NSCLC. Seven 
(22%) of 32 patients had significant renal cyst change after 
crizotinib treatment. These renal cysts developed early after 
crizotinib treatment and may be complex (Bosniak category 
III or higher) and resemble malignancy. However, after stop-
ping crizotinib, the cysts regressed spontaneously. Patients 
with significant renal cysts change had received more anti-
cancer treatment prior to crizotinib and had a longer crizotinib 
treatment duration.
Renal cysts development after crizotinib treatment 
seems to have a benign course. In the representative patients 
1 and 2, new renal cysts developed after crizotinib was started 
and regressed after withholding crizotinib. Renal function 
was impaired as the cysts progressed only in patient 1 after 
6 months of crizotinib treatment. Her renal function returned 
to baseline after stopping crizotinib. However, after crizotinib 
rechallenge, her renal function was unaffected. In the present 
cohort, the lung cancer continues to be responsive to crizo-
tinib even after developing complex renal cyst. The complex 
renal cysts should not be mistaken as new metastases and pre-
clude crizotinib use.
The prevalence of renal cyst before crizotinib is high 
(23 of 32, 72%) in our study cohort. Prevalence of renal 
cyst is reported variably. In autopsy, more than 50% of 
patients aged over 50 have at least one simple renal cyst.6 As 
medical imaging advances, renal cysts are identified more 
TABLE 2.  Comparison of Patient Characteristics (n = 32)
Patients with Significant Renal  
Cyst Change (n = 7)
Patients Without Significant  
Renal Cyst Change (n = 25) p Value
Age 62 (44–69) 56 (51–62) 0.80
Male sex 3 (43%) 12 (48%) 0.99
Adenocarcinoma cell type 7 (100%) 24 (96%) 0.99
Never smoker 3 (43%) 18 (72%) 0.20
Stage IV at diagnosis 6 (86%) 15 (60%) 0.37
Underwent curative operation for lung cancer 1 (17%) 7 (28%) 0.65
Previous anti-cancer therapy (line) 5 (4–6) 3 (2–4) 0.04
Baseline creatinine (mg/dL) 0.8 (0.70–1.00) 0.9 (0.70–0.95) 0.50
Renal cyst presented before crizotinib 6 (86%) 17 (68%) 0.65
Crizotinib treatment duration (day)a 956 (583–963) 248 (136–512) 0.007
Progression-free survival after crizotinib (day)a 509 (247–837) 210 (123–471) 0.09
Continuous variables presented as median (first to third quartiles) and compared by Mann-Whitney U test.
aData recorded up until March 16, 2014.
TABLE 3.  Comparison of Patients with and Without Baseline Renal Cysts (n = 32)
Patients Without Baseline Renal  
Cyst (n = 9)
Patients with Baseline Renal  
Cyst (n = 23) p Value
Age 52 (44–65) 60 (51–64) 0.28
Male sex 2 (22%) 13 (57%) 0.12
Adenocarcinoma cell type 9 (100%) 22 (96%) 0.99
Never smoker 7 (78%) 14 (61%) 0.44
Stage IV at diagnosis 6 (67%) 15 (65%) 0.99
Underwent curative operation for lung cancer 2 (22%) 6 (26%) 0.99
Previous anti-cancer therapy (lines) 3 (1–5) 4 (2–5) 0.48
Baseline creatinine (mg/dl) 0.8 (0.70–0.90) 0.9 (0.70–1.00) 0.37
Significant renal cyst change 1 (11%) 6 (26%) 0.36
Crizotinib treatment duration (day)a 335 (112–852) 297 (178–837) 0.95
Progression-free survival after crizotinib (day)a 248 (168–425) 249 (126–509) 0.82
Continuous variables presented as median (first to third quartiles) and compared by Mann-Whitney U test.
aData recorded up until March 16, 2014.
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frequently.6 Using spiral computer tomography for screen-
ing for renal cysts, it is reported that the prevalence of renal 
cysts in patients aged 40–60, 60–80, and aged over 80 were 
27.5%, 49.0%, and 60.6%, respectively.9 Our patients were 
highly selected. It is not known if lung cancer or anticancer 
therapy can influence renal cyst development. Moreover, the 
case numbers are limited. There might also be selection bias. 
Although there was only one patient without baseline renal 
cyst developed new complex renal cyst, it is still possible 
that patients without baseline renal cyst can develop complex 
renal cyst after crizotinib therapy. In the latest FDA label for 
crizotinib published in November 2013,3 seven (4%) patients 
was reported to have renal cysts formation. The prevalence 
of renal cyst formation was much lower than our report 
(22%). It may be because of the different definition of “sig-
nificant renal cyst change” and lack of systematic review. 
In addition, in the FDA’s previous label published in August 
2011,10 only two patients (1%) was reported to have complex 
renal cyst formation. As crizotinib becomes more commonly 
prescribed, more patients with renal cyst formation may be 
reported. Most of the renal cysts formed reported in the FDA 
label, as our study, were complex renal cysts and some were 
very complicated and resembled abscess formation. Our 
patients did not have any signs of infection and were not 
treated with any antibiotics. The renal cysts persisted for 
months to years, regressed after withholding crizotinib and 
reappeared after resuming crizotinib. The cyst formations 
were not likely infectious processes.
It is worth emphasizing that patients who were enrolled 
into the trials were highly selected. They have received mul-
tiple lines of anti-cancer therapy and survived. The tumor 
biology and tumor–patient relationship in these patients may 
not be representative of the general population. Comparing 
patients with significant renal cyst change to those without, 
patients who received more previous anti-cancer chemother-
apy had more significant renal cyst change. The precise rea-
son is unknown. It may be related to the relative small patient 
numbers or there are still other mechanisms between renal 
cyst development and tumor responsiveness to treatment.
Crizotinib is an inhibitor of ALK and c-Met.1 c-Met 
is found in normal renal tissue but is limited to the cell mem-
brane and/or cytoplasm of epithelial cells in specific tubular 
segments.11 In c-Met knock-out mice, there are no significant 
defects in kidney morphology or function.12 In patients with 
autosomal dominant polycystic kidney disease (ADPKD), the 
hepatocyte growth factor (HGF), and its receptor c-Met are 
thought to contribute to cyst formation in an autocrine man-
ner.13 Another recent study demonstrates that c-Met may pro-
mote renal cystogenesis.14 In a mouse model of ADPKD, the 
inhibition of c-Met by Su-11274 and PHA-665752 lead to the 
inhibition of cystogenesis.15 It remains doubtful if crizotinib can 
have the opposite effect on renal cyst formation. Our patient 2 
whose crizotinib failed after 32 months of treatment was given 
alectinib for further lung cancer treatment. The complex renal 
cysts regressed significantly. It seems that renal cysts formation 
is not a class effect of ALK inhibitor. Mechanism of how crizo-
tinib contributes to renal cyst formation warrants further studies.
In conclusion, renal cysts change during crizotinib ther-
apy for ALK-positive advanced NSCLC is not uncommon. 
Development of complex renal cysts reverses after stopping 
crizotinib.
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